ArticleInternational journal of clinical and experimental medicine2015
Polymorphisms in the nuclear excision repair gene ERCC2/XPD and susceptibility to cutaneous basal cell carcinoma.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Association Between the Asp312Asn, Lys751Gln, and Arg156Arg Polymorphisms inTechnology in cancer research & treatment · 2017Article
- Conventional Versus Giant Basal Cell Carcinoma, a Review of 57 Cases: Histologic Differences Contributing to Excessive Growth.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies have investigated the relationship between XPD Lys751Gln and Asp312Asn genetic variants and risk of cutaneous basal cell carcinoma (BCC). However, the results remain inconclusive. We performed a meta-analysis, using a comprehensive strategy based on the allele model and a model-free approach, to investigate the association of between XPD Lys751Gln and Asp312Asn polymorphisms with BCC risk. For XPD Lys751Gln, no significant BCC risk was found in the allele model (OR = 0.97, 95% CI 0.90-1.04, I (2) = 35.3%, P heterogeneity = 0.125) and with model-free approach (ORG = 0.95, 95% CI 0.87-1.04, I (2) = 15.9%, P heterogeneity = 0.296). For XPD Asp312Asn, there was also no association between this polymorphism and BCC risk in the allele model (OR = 0.94, 95% CI 0.86-1.03, I (2) = 0, P heterogeneity = 0.650) and with the model-free approach (ORG = 0.94, 95% CI 0.85-1.05, I (2) = 0, P heterogeneity = 0.603). Therefore, this meta-analysis suggests that the XPD Lys751Gln and Asp312Asn polymorphisms were not associated with BCC risk. Further large and well-designed studies are needed to confirm these findings.
Indexed as
Identifiers
26379851PMC4565234W2412140361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.